By: Matthew Stenger From: ascopost.com In an analysis involving the phase III SENOMAC trial reported in The Lancet Oncology, de Boniface et al found that the use of completion axillary lymph node dissection (cALND) to identify pN2-3 status (at least four nodal metastases) in patients with breast cancer, and thus qualification for adjuvant CDK4/6 inhibitor treatment, was associated with a …
Partial Breast Irradiation Versus Whole Breast Irradiation for Early Breast Cancer Patients in a Randomized Phase III Trial
By: Birgitte V. Offersen, MD, PhD; Jan Alsner, MSc, PhD; Hanne M. Nielsen, MD, PhD; Erik H. Jakobsen, MD; Mette H. Nielsen, MD, PhD; Lars Stenbygaard, MD; Anders N. Pedersen, MD, PhD; Mette S. Thomsen, MSc, PhD; Esben Yates, MSc; Martin Berg, MSc; Ebbe L. Lorenzen, MSc, PhD; Ingelise Jensen, MSc; Mirjana Josipovic, MSc, PhD; Maj-Britt Jensen, MSc; and Jens …
Novel Agents in the Adjuvant Setting: PARP Inhibitors
By: Charles Geyer, MD, FACP From: onclive.com Dr Geyer and Dr Krop explore data from the OlympiA phase III trial of adjuvant olaparib in patients with variants in BRCA1/2. Dr. Charles Geyer: I would be happy to overview OlympiA real quick. Just a reminder, this is really a big, phase three, double blind, placebo-controlled trial that was designed to assess …
EMERALD Trial: Elacestrant vs Standard Endocrine Therapy in Previously Treated Patients With ER-Positive, HER2-Negative Advanced Breast Cancer
By: Matthew Stenger From: ascopost.com As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, and colleagues, the phase III EMERALD trial has shown prolonged progression-free survival with the oral selective estrogen receptor (ER) degrader elacestrant vs standard endocrine therapy among patients with previously treated ER-positive, HER2-negative advanced breast cancer, including those with an ESR1 mutation. Elacestrant …
Breast Cancer Patients with Estrogen Receptor Mutations May Benefit from Early Switch to Fulvestrant/Palbociclib
From: sabcsmeetingnews.org Among patients with hormone receptor-positive breast cancer treated with an aromatase inhibitor plus palbociclib, those who displayed a rising ESR1 mutation detected in their blood before disease progression doubled their median progression-free survival following a switch to fulvestrant plus palbociclib, according to results from the phase III PADA-1 clinical trial presented during Thursday’s General Session at SABCS 2021. …
Veru Launches Registrational Trial of Anti-Androgen Drug Enobosarm for Metastatic Breast Cancer
From: precisiononcologynews.com Veru, a Miami-based cancer drugmaker, on Wednesday said it has begun enrolling previously treated hormone receptor (HR)-positive, HER2-negative metastatic breast cancer patients in a Phase III trial of its anti-androgen receptor therapy enobosarm. The registration-directed trial, dubbed ARTEST, is specifically exploring the activity of enobosarm in advanced breast cancer patients with androgen receptor (AR)-positive and estrogen receptor (ER)-positive …
Trodelvy Improves QOL in Triple-Negative Breast Cancer
By: Greg Laub From: medpagetoday.com At the European Society for Medical Oncology (ESMO) virtual meeting, new data from the phase III ASCENT study was presented showing that patients with treatment-resistant metastatic triple-negative breast cancer (TNBC) who received sacituzumab govitecan (Trodelvy) had significant and clinically meaningful improvements in health-related quality of life (QOL). In this exclusive MedPage Today video, co-investigator Kevin …
Extended Letrozole Reduced Recurrence Risk in Postmenopausal Breast Cancer
By: Mike Bassett From: medpagetoday.com 5 years of the aromatase inhibitor improved disease-free survival vs 2-3 years Five years of extended treatment with the aromatase inhibitor letrozole significantly improved disease-free survival (DFS) compared with the standard duration of 2 to 3 years in postmenopausal patients with breast cancer who had already received 2 to 3 years of tamoxifen, according to …
Enhertu improves survival in Phase III breast cancer trial
From: europeanpharmaceuticalreview.com Enhertu (trastuzumab deruxtecan) significantly improved survival in the DESTINY-Breast03 Phase III head-to-head trial against trastuzumab emtansine. Positive high-level results from the head-to-head DESTINY-Breast03 Phase III trial has shown that Enhertu (trastuzumab deruxtecan) demonstrates superiority over trastuzumab emtansine (T-DM1) in treating HER2-positive metastatic breast cancer. Enhertu is an HER2-directed antibody drug conjugate (ADC) developed by AstraZeneca and Daiichi Sankyo, …
Analysis of MINDACT Study Confirms MammaPrint Accurately Identifies Extremely Indolent Ultra Low Risk Breast Cancers
From: businesswire.com Oral presentation at ASCO 2021 highlights long term data with higher than 99% 8-year breast cancer specific survival for patients with MammaPrint Ultra Low Risk status regardless of clinical risk Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that data from the landmark MINDACT study will be shared at the 2021 American Society …